Medical Weight Loss

  • Using a weightloss compound as a treatment method for improving glycemic control and shows great promise for patients who are having difficulty losing weight. Studies have demonstrated that it reduced appetite, improved control of eating, and reduced food cravings in addition to improved glycemic control. The greatest benefits weight loss benefits were observed when the formula is used in combination with lifestyle changes, such as improved diet and consistent exercise.

  • The formula mimics a hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion, thereby lowering blood sugar. It has demonstrated beneficial effects on glycemia, in addition to a host of other benefits.

  • It as a subcutaneous injection which is dosed based upon your body composition and goal weight. You are given weekly injections, where the dosage will gradually increase as your body becomes tolerant.

    This medication is generally well-tolerated and can be dosed continuously without breaking treatment with no diminishing effects.

  • Increased postprandial insulin secretion

    Decreased food cravings

    Delays gastric emptying

    Associated with decreased appetite, by potentially increasing leptin sensitivity

    Increased satiety

  • On June 4, 2021 the FDA approved it for weight loss. The Food & Drug Administration approved this medication injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced-calorie diet and increased physical activity. This under-the-skin injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.

  • The most commonly reported side effects to include nausea, vomiting, diarrhea, stomach pain, and constipation. The risk of serious side effects increases in patients with hypoglycemia, kidney problems, and risk of allergic reactions.

    *Medical or Family history of medullary thyroid cancer, pancreatitis, or MEN2 (a rare genetic endocrine tumor disorder) are not permitted to be in the program.